On the subject in the title: Private prescribing in the UK: what is actually involved Working notes rather than a conclusion.
The question about private prescribing that I actually want answered is the second one below. The first is context and I have kept it short.
Both are stated with units, and I have said what I already checked so that nobody repeats it.
Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.
Narrowing post #2, because the general version has more than one answer.
The version of private prescribing that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Everything in the opening post holds. The case it does not cover is the one I have.
Availability through a private route and availability through the public system are separate questions and both change independently.
This follows post #2 rather than contradicting it.
I have been on both sides of the private prescribing argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
Private prescribing arrangements differ in what they include, and the differences are more consequential than the headline price.
I looked this up rather than remembered it, which is the right order.
MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.
That is the version I use. It may not be the version that is correct.
Where I part company with post #9, and it is a narrow parting.
I would call the community position on private prescribing likely rather than established, and I would be comfortable defending that hedge.
Where I part company with post #7, and it is a narrow parting.
Counterpoint on private prescribing, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the dull one out.
Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.
That distinction has done more work for me than anything else in this category.
This is the first time the answer has come with its own limits attached. Appreciated.
What I can speak to on private prescribing is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Ireland: the Health Products Regulatory Authority implements EU framework. Prescription-only. Reimbursement for weight management has been more restrictive than for diabetes. Private prescription at full cost is usual for weight management.
The number is defensible. The precision I gave it is not.
One more thing on private prescribing that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
Cross-border movement between the two jurisdictions is not the same as domestic movement within either, and the rules are published rather than inferred.
If this contradicts something upthread, the upthread version may well be the better one.
That is the distinction I keep failing to hold on to. Written down now.
Taking post #18 at face value and following it one step further.
Distinguishing three things in the private prescribing discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Adding a note of thanks rather than an opinion. I did not know most of that.
I read post #22 twice before replying, because I had assumed the opposite.
An update on my earlier private prescribing post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
Building on post #24 rather than restating it.
Adding a null result on private prescribing. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.
What I would tell a new member reading about private prescribing for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Private prescribing has been discussed here with more heat than it deserves, mostly because two definitions have been in play the whole time.
Private prescribing arrangements differ in what they include, and the differences are more consequential than the headline price.
Someone should write this up properly, and it should probably not be me.